A row between Wes Streeting and pharmaceutical companies has intensified after drugmakers rejected the health secretary’s latest offer on NHS drug pricing.
The two sides failed to reach agreement by a midday deadline on Friday, meaning the mechanism under which the health service claws back some of the money it pays for medicines will continue at a rate the industry said was “unsustainable” and could ultimately disadvantage patients.
